Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1571-1581

  Sorrentino, Carlo ^a   Musiani, Piero ^a   Pompa, Paolo ^b   Cipollone, Giuseppe ^a   Di Carlo, Emma ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SS Annunziata Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; FLUTAMIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; LEUPRORELIN; PERFORIN; T CELL INTRACELLUAR ANTIGEN 1; T LYMPHOCYTE ANTIGEN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; LYMPHATIC DRAINAGE; LYMPHOCYTIC INFILTRATION; MACROPHAGE FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TISSUE SECTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY;

EID: 79952729234     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2804     Document Type: Article

References (48)

1. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;4:CD006019.
2. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neoadjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9-17.
3. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565-70. (Pubitemid 33121432)
4. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49. (Pubitemid 40568683)
5. Di Carlo E, D'Antuono T, Pompa P, Giuliani R, Rosini S, Stuppia L, et al. The Lack of Epithelial Interleukin-7 and BAFF/BLyS Gene Expression in Prostate Cancer as a Possible Mechanism of Tumor Escape from Immunosurveillance. Clin Cancer Res 2009;15:2979-87.
6. Di Carlo E, Magnasco S, D'Antuono T, Tenaglia R, Sorrentino C. The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21. Prostate 2007;67:1070-80. (Pubitemid 46983336)
7. Cooke PS, Young P, Cunha GR. Androgen receptor expression in developing male reproductive organs. Endocrinology 1991;128:2867-73.
8. Hofmeister R, Khaled AR, Benbernou N, Rajnavolgyi E, Muegge K, Durum SK. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev 1999;10:41-60. (Pubitemid 29230851)
9. Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med 2009;266:141-53.
10. Pores-Fernando AT, Zweifach A. Calcium influx and signaling in cytotoxic T-lymphocyte lytic granule exocytosis. Immunol Rev 2009;231:160-73.
11. Griffiths GM, Mueller C. Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. Immunol Today 1991;12:415-9
12. Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 1997;4:32-40. (Pubitemid 27076437)
13. Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis I, et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 1998;28:961-72. (Pubitemid 28116209)
14. Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, Schwartzman JD, et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000;12:483-94.
15. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3. Science 2003;299:1057-61. (Pubitemid 36222930)
16. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-11. (Pubitemid 44036276)
17. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells. J Exp Med 2001;194:847-53. (Pubitemid 32983019)
18. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokine thymus and activation-regulated chemokine and machrophage-derived chemokine. Int Immunol 1999;11:81-8. (Pubitemid 29037591)
19. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009;182:5693-701.
20. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71.
21. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43. (Pubitemid 43011261)
22. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93. (Pubitemid 47041232)
23. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009;137:1270-79.
24. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, et al. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 2004;92:221-36. (Pubitemid 40136583)
25. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
26. Ashcroft GS, Mills SJ. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest 2002;110:615-24. (Pubitemid 34988785)
27. Murray R, Suda T, Wrighton N, Lee F, Zlotnik A. IL-7 is a growth and maintenance factor for mature and immature thymocyte subsets. Int Immunol 1989;1:526-31. (Pubitemid 19258086)
28. Hock H, Dorsch M, Diamantstein T, Blankenstein T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991;174:1291-8.
29. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 2009;182:6951-8.
30. Watanabe M, Ueno Y, Yajima T, Iwao Y, Tsuchiya M, Ishikawa H, et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest 1995;95:2945-53.
31. Kröncke R, Loppnow H, Flad HD, Gerdes J. Human follicular dendritic cells and vascular cells produce interleukin-7: a potential role for interleukin-7 in the germinal center reaction. Eur J Immunol 1996;26:2541-4. (Pubitemid 26340962)
32. Golden-Mason L, Kelly AM, Traynor O, McEntee G, Kelly J, Hegarty JE, et al. Expression of interleukin 7 (IL-7) mRNA and protein in the normal adult human liver: implications for extrathymic T cell development. Cytokine 2001;14:143-51. (Pubitemid 32579323)
33. Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent anti-tumor response in vivo. J Exp Med 1993; 178;1057-65. (Pubitemid 23260444)
34. Cavallo F, Di Carlo E, Butera M, Verrua R, Colombo MP, Musiani P, et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 1999;59:414-21. (Pubitemid 29048877)
35. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997;8:207-19. (Pubitemid 28077928)
36. Shen H, Lentsch AB. Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am J Physiol Cell Physiol 2004;286:C840-7.
37. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
38. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J Biol Chem 1996;271:21514-21. (Pubitemid 26293018)
39. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-80. (Pubitemid 29399540)
40. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, et al. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 1999;104:1097-105. (Pubitemid 29536320)
41. Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, et al. Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 2000;165:2205-13. (Pubitemid 30648752)
42. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66:5716-22. (Pubitemid 43927124)
43. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
44. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-45.
45. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006;25:6868-86. (Pubitemid 44657857)
46. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680-4. (Pubitemid 44657845)
47. Bettoun DJ, Scafonas A, Rutledge SJ, Hodor P, Chen O, Gambone C, et al. Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways. J Biol Chem 2005;280:38898-901. (Pubitemid 41713838)
48. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 1998;83:1995-2002. (Pubitemid 28503732)